MIMETAS Revenue and Competitors
Estimated Revenue & Valuation
- MIMETAS's estimated annual revenue is currently $18.5M per year.
- MIMETAS's estimated revenue per employee is $170,000
Employee Data
- MIMETAS has 109 Employees.
- MIMETAS grew their employee count by -20% last year.
MIMETAS's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Biology | Reveal Email/Phone |
2 | VP Business Development | Reveal Email/Phone |
3 | Associate Director / Head fee-for-service department | Reveal Email/Phone |
4 | Director Biology Discovery | Reveal Email/Phone |
5 | Director Manufacturing | Reveal Email/Phone |
6 | Associate Director TechCore | Reveal Email/Phone |
7 | Chief Technology Officer | Reveal Email/Phone |
8 | Biomaterials Manager | Reveal Email/Phone |
9 | Intellectual Property Manager | Reveal Email/Phone |
10 | Research Manager | Reveal Email/Phone |
MIMETAS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.9M | 24 | -4% | N/A | N/A |
#2 | $71.4M | 336 | 23% | N/A | N/A |
#3 | $5.2M | 38 | -5% | N/A | N/A |
#4 | $5.4M | 40 | 18% | N/A | N/A |
#5 | $5.2M | 38 | -10% | N/A | N/A |
#6 | $18.5M | 109 | -20% | N/A | N/A |
#7 | $71M | 329 | 15% | $31.5M | N/A |
#8 | $4.1M | 30 | 76% | N/A | N/A |
#9 | $22.6M | 133 | 11% | N/A | N/A |
What Is MIMETAS?
High-throughput Human Disease and Tissue Models MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
keywords:N/A
N/A
Total Funding
109
Number of Employees
$18.5M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
MIMETAS News
CN Bio Tissues, Mimetas Insphero, Ascendance Bio, Kirkstall , Hurel , Synvivo , Axosim and Nortis. This Organs-on-chips Market report covers...
LEIDEN, The Netherlands, April 19, 2022 / B3C newswire / -- MIMETAS, a global leader in organ-on-chip-based disease models, is a partner in...
Mimetas BV participating in 325m cancer funding. © Oncode Institute. 20.04.2022 by tg. Organ-on-chip disease model specialist Mimentas BV participates in a...
Emulate, CN Bio, Tissuse, Mimetas, Insphero, Ascendance Bio, Kirkstall, Hurel, Synvivo, Axosim, Nortis. Geographical Analysis: North America, ...
... Analysis, Technology and Global Industry Trends by 2027 Top Key Vendors-REPROCELL, 3D Biotek, Nano3D Biosciences, MIMETAS.
Other Companies in Leiden
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.1M | 110 | -10% | N/A |
#2 | $15.7M | 112 | 22% | N/A |
#3 | $27.2M | 112 | 40% | N/A |
#4 | $30.8M | 114 | 33% | N/A |
#5 | $25.5M | 116 | 5% | N/A |